Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Dalazatide in Healthy Volunteers
NCT02446340Phase 1Completed
- Sponsor
- Kineta Inc.
- Start
- Nov 2013
- Primary completion
- Apr 2014
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dalazatide in psoriasis (4 arms), sponsored by Kineta Inc. Primary endpoint: Subjects with adverse events at Day 57. Started Nov 2013; status: completed.
02
Drugs
dalazatide
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02446340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446340.